Technical Analysis for RANI - Rani Therapeutics Holdings, Inc.

Grade Last Price % Change Price Change
C 21.495 5.78% 1.18
RANI closed down 1.69 percent on Tuesday, January 18, 2022, on 57 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions.

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent N/A Down Up
Historical RANI trend table...

Date Alert Name Type % Chg
Narrow Range Bar Range Contraction 5.78%
NR7 Range Contraction 5.78%
Upper Bollinger Band Walk Strength 5.78%
Inside Day Range Contraction 5.78%
Wide Bands Range Expansion 5.78%
Pocket Pivot Bullish Swing Setup 3.99%
Upper Bollinger Band Walk Strength 3.99%
Multiple of Ten Bullish Other 3.99%
Wide Bands Range Expansion 3.99%
Upper Bollinger Band Touch Strength 3.99%
Older End-of-Day Signals for RANI ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.


Rani Therapeutics Holdings, Inc. Description

Rani Therapeutics Holdings, Inc. operates as a clinical stage biotherapeutics company that develops orally administered biologics. The company develops the RaniPill capsule, a platform that is intended to replace subcutaneous or IV injection of biologics with oral dosing. Its product pipeline includes RT-101, an octreotide, which has completed Phase I clinical trial for the treatment of neuroendocrine tumors and acromegaly; RT-105, an anti-TNF-alpha antibody to treat psoriatic arthritis; RT-102, a parathyroid hormone that is in preclinical studies for the treatment of osteoporosis; RT-109, a human growth hormone to treat growth hormone deficiency; RT-110, a parathyroid hormone for the treatment of hypoparathyroidism; RT-103, a glucagon-like peptide-1 mimetic to treat type 2 diabetes; and RT-106, a basal insulin for the treatment of type 2 diabetes. The company was founded in 2012 and is headquartered in San Jose, California.


Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Organ Systems Diabetes Anatomy Endocrine System Osteoporosis Peptide Hormones Growth Hormone Glands Growth Hormone Deficiency Neuroendocrine Tumors Parathyroid Hormone Acromegaly Glucagon Psoriatic Arthritis Hypoparathyroidism Neuroendocrinology Treatment Of Osteoporosis

Is RANI a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength


Indicator Value
52 Week High 36.0
52 Week Low 9.24
Average Volume 64,341
200-Day Moving Average 0.00
50-Day Moving Average 22.58
20-Day Moving Average 18.23
10-Day Moving Average 18.42
Average True Range 2.28
ADX 19.4
+DI 21.52
-DI 15.10
Chandelier Exit (Long, 3 ATRs) 16.10
Chandelier Exit (Short, 3 ATRs) 22.34
Upper Bollinger Bands 21.55
Lower Bollinger Band 14.91
Percent B (%b) 0.82
BandWidth 36.39
MACD Line -0.36
MACD Signal Line -1.04
MACD Histogram 0.6798
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 21.68
Resistance 3 (R3) 21.73 21.33 21.46
Resistance 2 (R2) 21.33 20.98 21.30 21.38
Resistance 1 (R1) 20.82 20.76 21.07 20.77 21.31
Pivot Point 20.42 20.42 20.54 20.39 20.42
Support 1 (S1) 19.91 20.07 20.17 19.87 19.33
Support 2 (S2) 19.51 19.85 19.48 19.26
Support 3 (S3) 19.00 19.51 19.18
Support 4 (S4) 18.96